Delving into the Latest Updates on Thiocolchicoside with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

TCC, Thiocolchicine 2-glucoside analog, Thiocolchicoside (INN)

+ [4]

Target

GABAA receptor

Mechanism

GABAA receptor antagonists(Gamma-aminobutyric acid A receptor antagonists)

Therapeutic Areas

Nervous System DiseasesSkin and Musculoskeletal Diseases

Active Indication

Muscle Spasticity

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC27H33NO10S

InChIKeyLEQAKWQJCITZNK-AXHKHJLKSA-N

CAS Registry602-41-5

Irritable bowel syndrome (IBS) is a gastrointestinal transit disorder characterized by chronic abdominal pain and impaired transit in the absence of demonstrated organic disease. Considered a non-fatal disease, its effects relate more to quality of life, work production and health care systems.
Given the complexity of this disease, no treatment has been recognized as standard treatment. The treatment is rather focused on treating the symptoms caused (chronic pain or intestinal transit disorder). In general, therapy is considered individualized and includes lifestyle/diet modifications and pharmaceutical therapy.
Several published case studies evaluating the effect of mesotherapy on improving the severity of the disease have demonstrated an improvement in the symptoms of this syndrome. Due to the limited number of case studies and the insufficient level of evidence to conclude, our study will therefore be a before-and-after intervention study, to evaluate the effect of four mesotherapy sessions on the treatment of IBS symptoms.

Start Date28 Feb 2024

Sponsor / Collaborator

Polyclinique de l'Europe SASU

CTRI/2022/12/047988 / Not yet recruitingNot ApplicableIIT

Evaluating Pre-Emptive Analgesia of Etoricoxib, Thiocolchicoside and Dexamethasone in Lower Third Molar Surgery A Randomised Controlled Trail

Start Date11 Dec 2022

Sponsor / Collaborator-

CTRI/2022/07/043690 / RecruitingPhase 4

A Prospective, Randomized, Parallel Group, Open Label, Multi-centric, Active Controlled Study to Evaluate the Efficacy and Safety of fixed dose combination of Etoricoxib(60mg) and Thiocolchicoside (4mg) vs Chlorzoxazone(500mg) and Diclofenac(50mg) and Paracetamol(325mg) in Low Back Pain.

Start Date06 Jul 2022

Sponsor / Collaborator

Mankind Pharma Ltd.

100 Clinical Results associated with Thiocolchicoside

Login to view more data

100 Translational Medicine associated with Thiocolchicoside

Login to view more data

100 Patents (Medical) associated with Thiocolchicoside

Login to view more data

658

Literatures (Medical) associated with Thiocolchicoside

31 Dec 2024·Journal of Dermatological Treatment

Postoperative risk assessment of post-inflammatory hyperpigmentation and the efficacy of delayed prevention following 532 nm Q-switched Nd:YAG laser treatment of solar lentigines: a randomized controlled study

Article

Author: Lew, Bark-Lynn ; Lee, Yoonsung ; Choi, Sang-min ; Kim, Man S. ; Kang, Da-Hyun ; Kwon, Soon-Hyo

BACKGROUNDAlthough post-inflammatory hyperpigmentation (PIH) is a common adverse event following laser procedures, studies evaluating its risk remain limited.OBJECTIVETo analyze PIH risk after 532 nm Q-switched Nd:YAG laser (QSNYL) treatment for solar lentigines and examine the efficacy of triple combination cream (TCC) for its prevention.METHODSIn this single center, investigator-blinded, randomized controlled study, participants with solar lentigo either received TCC or emollient from 2 weeks post-QSNYL treatment. The occurrence of PIH was determined by three independent and blinded dermatologists. In vivo skin measurements and sun exposure questionnaires were examined to evaluate the risk of PIH.RESULTSA total of 28 patients with 67 solar lentigines were included in the analysis. In the control group, PIH occurred in 55.3% of the lesions. Risk factors for the occurrence of PIH were the increased erythema at weeks 2 (OR, 1.32; p = 0.035) and outdoor activity during 1-5 pm (OR, 8.10; p = 0.038). Treatment with TCC from 2 weeks post-QSNYL treatment significantly decreased the incidence of PIH (31.0% vs. 55.3%, p = 0.048).CONCLUSIONPost-laser erythema and outdoor activity at the daytime are prognostic factors for the occurrence of PIH. Administering TCC could be considered for the prevention of PIH in high-risk patients.

31 Dec 2024·Renal Failure

The role of hemodialysis access in intradialysis and interdialysis vital sign variabilities and the development of dialysis headache

Article

Author: You, Nujia ; Xiong, Yuqin ; Liao, Ruoxi ; Yu, Yang ; Qin, Shuoyue

To determine the relationship of hemodialysis access with vital sign variability and hemodialysis-related headache (HRH). Adult outpatients receiving maintenance hemodialysis (MHD) were prospectively recruited, and 12 consecutive dialysis sessions were monitored. Intradialysis (hour-to-hour) and interdialysis (dialysis day-to-day) vital sign variabilities were assessed via three metrics: the difference between the maximum and minimum values, average real variability (ARV), and residuals. Multivariate logistic regression analysis was used to explore the factors triggering HRH. A total of 91 Chinese MHD patients (60.4% male) aged 58.5 ± 17.2 years were included, with 59 patients using radiocephalic arteriovenous fistulas (RCAVFs) and 32 patients using tunneled cuffed catheters (TCCs) for dialysis. The median dialysis vintage was 26.8 (12.0-44.7) months. Compared with the RCAVF group, the TCC group had significantly greater urea reduction (71.1 ± 9.3% vs. 61.7 ± 10.5%, p < 0.001) and clearance (1.5 (1.2-1.8) vs. 1.1 (1.0-1.4), p < 0.001) rates, higher intradialysis pulse variability and lower intradialysis diastolic blood pressure variability. Some of interdialysis variability indexes in pulse, systolic blood pressure (SBP), and SpO2 were significantly greater in the TCC group than that in the RCAVF group. Age (OR = 0.880, 95% CI = 0.785-0.986, p = 0.028), TCC use (OR = 22.257, 95% CI = 1.190-416.399, p = 0.038), intradialysis SBP-ARV (OR = 2.768, 95% CI = 1.069-7.171, p = 0.036), and blood sodium level (OR = 0.400, 95% CI = 0.192-0.832, p = 0.014) were shown to be independent risk factors for HRH. In conclusion, the use of TCCs has multifaceted effects on intradialysis and interdialysis vital sign variabilities and is independently associated with an increased risk of HRH.

01 Dec 2024·Journal of Hazardous Materials

Triclocarban disrupts the activation and differentiation of human CD8+ T cells by suppressing the vitamin D receptor signaling

Article

Author: Zhang, Xingwei ; Chang, Yiming ; Chen, Zhixi ; Li, Yangqiu ; Sun, Guodong ; Li, Xinye ; Zhang, Yikai ; Liu, Zirui ; Zha, Xianfeng ; Guo, Jiafan

Triclocarban (TCC) is a widely applied environmental endocrine-disrupting chemical (EDC). Similar to most of EDCs, TCC potentially damages the immunity of various species. However, whether and how TCC impacts the adaptive immunity in mammals has yet to be determined. Herein, we discovered that TCC disrupts the activation and differentiation of CD8⁺ T cells in primary human peripheral blood samples, purified CD8⁺ T cells, and in mice in vivo. Mechanistically, TCC might block the activation of the vitamin D receptor (VDR) and reduce the synthesis of cholesterol, a precursor of vitamin D, resulting in inhibition of VDR signaling due to the suppression of both its ligand and the receptor itself by TCC. Our findings elucidate the hazard and potential mechanisms of TCC in mammalian adaptive immunity and highlighted VDR as a potential therapeutic target for the immunodeficiency caused by TCC.

100 Deals associated with Thiocolchicoside

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D07276	Thiocolchicoside	M03BX05	DB11582

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Muscle Spasticity	-	-	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IEC2007	Not Applicable	-	-	Thiocolchicoside	madlhbcmhs(kvofrcedev) = jkizuwcudy vuktjaeqbq (duiqbxqzau ) View more	-	07 Jul 2007
EULAR2002	Not Applicable	Acute low back pain	-	Thiocolchicoside	(madwiwyehg) = nouaubalcm ukanthtfqa (vhwgeojdvq ) View more	Positive	12 Jun 2002
EULAR2002	Not Applicable	Acute low back pain	-	Tizanidine	(madwiwyehg) = zfdyofgbau ukanthtfqa (vhwgeojdvq ) View more	Positive	12 Jun 2002